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Neurodegenerative diseases (NDs) take a wide spectrum of pathologies and have a tendency to 
present themselves later in life. Neurodegenerative diseases affect 6 million Americans annually 
with ~1 million currently living with Parkinson’s disease (PD). One of the greatest contributors 
to the pathogenesis of neurodegenerative diseases is the occurrence of a traumatic brain injury 
(TBI) during life.  
 
All-trans-retinoic acid (atRA) is the active metabolite of Vitamin A. The retinoic acid pathway is 
known to be activated following TBI and is reduced in PD patients. Previous studies found a 
decrease in inflammation and behavioral deficits following administration of Vitamin A or atRA 
post TBI.  Retinoic acid receptor stimulation has been found to protect dopaminergic neurons of 
the substantia nigra. Studies have shown that endogenous atRA within brain tissue supports 
neuronal protection, axonal growth, inflammatory modulation, and glial differentiation. Retinoic 
acid metabolism blocking agents (RAMBAs) are emerging as new therapeutic interventions with 
the goal of increasing endogenous atRA brain concentration, for the treatment of TBI and PD.  
 
Our hypothesis was that instead of directly activating retinoic acid receptors, inhibition of the 
metabolism of atRA produced after central nervous system injury will have a neuroprotective 
effect and reduce the development of neurodegenerative diseases or cognitive impairments 
induced by TBI. This research sourced a newly synthesized RAMBA, DX308, for the purpose of 
confirming its action as a CYP26A1/B1 inhibitor. The aim of this project was to determine 
DX308 binding mode, and to characterize the effect of DX308 on atRA signaling in vitro. 
Modeling DX308-CYP26A1/B1 ligand-protein interaction was performed in order to support 
competitive binding of DX308. Glial- and neuroblastoma cell culture experiments were the 
preliminary investigation into DX308 as a functional RAMBA within the central nervous 
system.  
 
DX308 was shown to have a binding mode similar with tazarotenic acid, and atRA. Treatment of 
SNB19 and SHSY5Y cells with atRA dose dependently modulated retinoid-responsive genes. 
DX308 potentiated the effects of a nanomolar concentration of atRA in SNB19 however, this 
effect was not confirmed in SHSY5Y. Follow up experiments involving SHSY5Y atRA/TPA 
dopaminergic differentiation displayed an altered dopamine receptor expression compared to 
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1. Introduction & Background 
 Neurodegenerative diseases have long been a challenging area for both research scientists 
and healthcare professionals alike. Characterized by the progressive degeneration of a neuronal 
population, or group of neurons, the pathology progresses to affect cognitive and motor functions 
associated with the central and peripheral nervous system. Unfortunately, the prevalence of 
becoming diagnosed with a neurogenerative disease increases dramatically after the age of 65 
(Prince et. al., 2013).  Genetic and environmental factors contribute to the neurodegenerative 
pathophysiology with most diseases caused by protein misfolding and subsequent aggregation. 
Tauopathies, amyloidosis, α-synucleinopathies, and other misfolded proteins all contribute to 
neurodegenerative diseases such as dementia, Alzheimer’s, Huntington’s, and Parkinson’s 
disease (Dugger & Dickson, 2017). Adding insult to injury, traumatic brain injuries are 
associated with the pathogenesis of α-synuclein and amyloid-beta plaque formation, resulting in 
neurodegenerative diseases such as Alzheimer’s and Parkinson’s in later years of life. While the 
direct mechanisms are unknown associations between the biochemical cascade, cytotoxicity, and 
latent traumatic brain injury signaling sequalae all point to dysfunctional homeostatic process 
revolving around increased inflammatory signaling (Ladak et al., 2019).  
 Current treatments for neurodegenerative diseases often involve barbiturates and 
antipsychotics that target neurotransmitter signaling and transportation, often affecting quality of 
life for patients (Fox et al., 2011). Recently retinoid therapy has been proposed as retinoic acid 
signal transduction is induced after a traumatic brain injury and is reduced in Parkinson’s disease 
patients later on in life. All-trans retinoic acid signaling is shown to be associated with multiple 
genes involved in neurodegenerative pathogenesis and the inflammatory response (Goodman & 
Pardee, 2003). Additionally, endogenous regulation of retinoic acid in the adult brain supports 
neuronal protection, axonal growth, glial differentiation, and inflammatory modulation (Mey, 
2006). This research investigates the potential for a novel RAMBA, DX308, to target atRA 
metabolism in an effort to increase endogenous all-trans retinoic acid signaling. We hope that 
preliminary research for DX308’s use in the central nervous system will allow for future 
therapeutics to treat traumatic brain injuries and subsequent neurodegenerative diseases without 




1.1 Traumatic Brain Injury 
 Traumatic brain injuries (TBIs) are caused by blunt force trauma to the head or skull and 
can be classified as an open or closed injury based on the integrity of the skull and dura matter 
(Morrow & Pearson, 2010). The mechanical forces trigger vascular ruptures, glial/astrocyte 
activation, inflammation, and apoptosis resulting in neuronal tissue loss and cognitive 
impairment (Ladak, et al., 2019). TBIs were projected to be the third leading cause of death in 
2020, with 10 million occurring worldwide annually, and the United States accounting for 1.7 
million (W.H.O., 2002). The direct mechanical damage is defined as the primary
Figure 1.1: Traumatic Brain Injury Overview. A) Causation distribution in the United States. B) Ratio of severity. C) Primary and secondary pathophysiology 
and interplay.  




(1o) insult and is characterized as the physiologic cause of cell death. This 1o injury manifests 
itself as damage to neuronal tissue, blood vessels, and the initiation of the biochemical cascade 
which leads to the secondary (2o) insult, characterized by excitotoxic cell death (Mioni et al., 
2014). The 2o injury, initiated within minutes to hours after 1o insult, is characterized by the 
release of neurotransmitters (NT), cytokines, and transcription factors which form a biochemical 
signaling storm. This biochemical signaling cascade is the molecular basis for the 2o insult and 
causes widespread excitotoxity in the form of nitric oxide (NO), reactive oxygen species (ROS), 
and inflammation that in turn initiate apoptosis and necrosis (Abdul-Muneer et al., 2015) (Figure 
1.1). Traumatic brain injuries can be associated with Alzheimer’s and Parkinson’s disease, 
chronic traumatic encephalopathy, and epilepsy years to decades after the initial injury (Ladak, et 
al., 2019). Current treatments have a wide range of action due to the spectrum or intensity of 
injury. These treatments can range from raising the head and drug administration, to surgical 
intervention (Galgano et al., 2017). Interestingly, recent studies in the murine model show that 
treatment of TBI with all-trans-retinoic acid (atRA) can reduce lesion size, reactive astrogliosis, 
and axonal injury over seven days post injury (Hummel., et al 2020). Taken together, TBIs take 
on a wide spectrum of classifications and depending on the intensity of mechanical impact can 
produce a biochemical cascade which induces glial activation and astrogliosis resulting in cell 
death. Targeting the initiation and proliferation of the 2o insult is a primary target for drug 
intervention.  
1.1.1 Signaling Cascade 
 Following the 1o insult behind a TBI the blood brain barrier and neuronal cells are 
compromised, and excitotoxicity takes place as glutamate (Glu) levels are elevated in the 
extracellular space. Working in coordination with N-methyl-D-aspatic acid (NMDA) receptors, 
Glu and glycine bind to the receptors to cause Ca2+/Na+ influx and further downstream signaling 
that leads to cytotoxicity (Gao, 2016). Depolarization of neuronal populations also occurs after 
TBIs and can be a result of the glutamate storm from damaged vascular tissue (Hinzman et al., 
2016). Membrane depolarization, caused by Ca2+/Na+ influx can activate voltage gated calcium 
channels (VGCCs) that can increase intracellular Ca2+ concentrations and strengthen 
depolarization (Wolf et al., 2001). Continued depolarization leads to further neurotransmitter 
(NT) release and a cyclical process of cytotoxic signaling occurs triggering neuronal damage or 
death and subsequent inflammatory response. Increased calcium levels result in activated 
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calpains, a cystine protease, which is associated with cytoskeleton proteins, membrane proteins, 
cell adhesion molecules, and other protein kinases (Takahashi et al., 1990). Together, calpain in 
the presence of high Ca2+ concentrations compromises membrane integrity across the cell and 
influences signaling kinases for further downstream signaling. Sustained increased Ca2+ 
concentration further degrades the mitochondrion membrane by acting on mitochondrial 
permeability transition pore. Once active, this non-specific pore allows protons and Ca2+ to flow 
freely out of the mitochondria, effectively uncoupling oxidative transport chain and reducing 
adenosine triphosphate (ATP) synthesis. The reduction of ATP energy stores in the cell lead to 
further downstream signaling and necrosis (Halestrap, 2009). Once the mitochondrial membrane 
is compromised and ATP stores are depleted increased ROS and caspase-mediated apoptosis 
lead to cell death (Cheng et al., 2012). This signaling cascade begins minutes to hours after the 1o 
insult and is the primary therapeutic target for pharmacological intervention.  
1.1.2 Neuroinflammation & Gliosis 
 Neuroinflammation is considered to be an essential part of the 2o insult response. This 
process involves a response mediated by microglia, and astrocytes. The release of cytokines and 
damage to blood vessels due to 1o mechanical insult also allows for leukocytes to invade the 
central nervous system (CNS). This initial response is guided by a cytokine storm that can be 
detrimental to neuronal survival (Hernandez et al., 2013). Resting microglia become activated in 
minutes after the 1o insult. Active microglia cells take the form of non-phagocytic and 
phagocytic phenotypic states around the area of injury. Activated microglia become polarized 
into M1 and M2 “classifications” respectively. M1-non-phagocytotic microglia secret 
proinflammatory cytokines and neurotoxins such as: TNF-⍺, IL-1β, IL-6, NO, and ROS. These 
cytokines further damage the blood brain barrier (BBB) and signal additional inflammation 
downstream. M1 microglia also activate induced nitric oxide synthase (iNOS) and Nf-kB 
pathways which lead to neurodegeneration. In contrast, M2-phagocytotic microglia are 
considered to be the anti-inflammatory counterpart to M1 proinflammatory signaling. M2 
microglia macrophages act to clean cellular debris and secret anti-inflammatory cytokines: IL-4, 
IL-10, IL-13, and transforming growth factor β (TGF-β) (Tang, 2016). These anti-inflammatory 
cytokines can work to combat the initial M1 inflammatory signaling. Additionally, M2 microglia 
are identified by Arginase 1 (Arg1) which competes with iNOS to utilize arginine for 
downstream signaling. iNOS uses L-arginine to produce NO and citrulline. Arg1 metabolizes L-
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arginine into urea and ornithine which are precursors to hydroxyproline, proline, and polyamine. 
Hydroxyproline and proline are constituents of collagen synthesis and contribute to extracellular 
matrix and tissue repair; while some polyaimines are required for cell proliferation and 
differentiation (Jenkins et al., 2003; Thomas & Thomas, 2001). This M1/M2 signaling 
competition during neuroinflammation is a prime target for TBI intervention. (Figure 1.2)  
 Reactive astrocytes also play a role in the neuroinflammatory response. Astrocytes are 
primarily responsible for maintaining the blood brain barrier (BBB) but can also produce 
neurotrophic factors, regulate NT and ion concentrations, and protect against neurotoxins.  
Astrocytes are identified by their expression of glial fibrillary acidic protein (GFAP) and 
dramatically increase the expression during a TBI. Astrocytes are pivotal in the formation of a 
glial scar, which occurs during a severe TBI. The glial scar acts to protect the rest of the brain 
from the 1o insult and ensuing 2o inflammatory signaling cascade. Astrocytes also play an 
important role in NT reuptake, specifically glutamate and gamma-aminobutyric acid (GABA). 
Additionally, astrogliosis activates several signaling pathways including: JAK-STAT, Nf-kB, PI-
3K/AKT, MAPK, and many more. All of which play an intersecting role in neuroinflammation 
of the CNS (Sonfroniew, 2009). Modification of these pathways in addition to targeting Glu and 
Figure 1.2: Activated Microglia as Therapeutic Target In Neurodegenerative Diseases. Special interest on guiding differentiation toward 
activated-M2-phagocytotic microglia post injury. 
Source: Tang et al. (2016), with permission from Springer Nature (lic. #: 5117921504519) 
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GABA transporters is a primary focus of therapy surrounding astrogliosis (Kumar & Loane, 
2012).  
1.1.3 Oxidative Stress 
Oxidative stress is a major contributor to the biochemical cascade which leads to apoptosis and 
necrosis following the 1o insult. Superoxide (O2
-
) is the most common ROS following TBI and 
can form H2O2 and OH-, and other ROS. After the 1o insult M1 microglia invade the damaged 
tissue and upregulate nicotinamide adenine dinucleotide phosphate oxidase (NOX2), 
subsequently producing large amounts of ROS (Kumar et al., 2016). ROS can cause a wide range 
of cell signaling dysfunction mediated by: DNA oxidation, lipid peroxidation, protein 
carbonylation, and disruption of the mitochondrial electron transport chain. Disruption of the 
mitochondrial membrane and electron transport chain increases ROS production and reduces 
available energy supplies (Cornelius et al., 2013). Lipid peroxidation damages the mitochondrial 
membrane and produces 4-hydroxylnonenal, a biproduct that dampens astrocyte Glu receptors 
and Ca2+ ATPase activity. This effectively strengthens the 2o insult with increased extracellular 
Glu and intracellular Ca2+ concentrations aiding apoptosis and necrosis. Together, the BBB is 
further compromised and the 1o insult is exacerbated by increasing Glu excitotoxity and Ca2+ 
mediated enzymatic activity (Durmaz et al., 2003; Mustafa et al., 2010).  
1.1.4 Current Treatments 
 Therapeutic intervention for TBIs takes into account several aspects and characteristics of 
the injury. Mild TBI, or concussions, can be treated with something as simple as rest and sleep. 
Most TBIs are diagnosed with magnetic resonance imaging technique. Moderate to severe TBIs 
may require immediate surgical intervention and can use biomarkers to better understand the 2o 
biochemical cascade that is occurring. TBI markers can be found in the blood or cerebral spinal 
fluid and include: GFAP, S100B protein, caspase-3, brain derived neurotrophic factor (BDNF), 
neuron-specific enolase, tau, glutamate, lactate, and others (Lorente, 2017). Current drug 
interventions such as barbiturates or prophylactics aim to lower the metabolic demand of the 
brain and decrease seizure events during early TBIs respectively (Galgano et al., 2017). Further 
interventions try and combat the biochemical cascade that occurs after the 1o insult which can 
have lasting effects for years. N-type calcium channel blockers such as, ziconotide, can improve 
mitochondrial function; while hyperosmolar drugs like mannitol work to decrease intercranial 
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pressure. Amantadine is a NMDA receptor antagonist and combats Glu mediated excitotoxicity 
by halting the flow of ions into the neuron. Interestingly, stem cell therapy could be an option for 
TBI. Grafting stem and progenitor cells to the damaged areas of CNS result in improved 
neuronal recovery (Galgano et al., 2017). Other novel drugs like anti-inflammatory molecule 
MW-151 are being tested in the murine model to alter cytokine signaling and microglia/astrocyte 
activation (Bachstetter et al., 2012). Novel drugs include NOX2 inhibitors which seem to favor 
M2 differentiation and proliferation in the mouse model by combating the production of ROS via 
M1 microglia activation (Kumar et al., 2016). Retinoid therapy has also been proposed for TBI 
intervention, with particular interest on attenuating the 2o insult.  Retinoic acid (RA) signal 
transduction has been shown to be activated when contusions, compressions, and lacerations 
occur in the nervous system (Mey, 2006). Recent studies show that endogenous RA in the brain 
supports neuronal protection, reduces axonal injury, and attenuates inflammatory signaling 
(Hummel et al., 2020). Targeting atRA metabolism by administering a small molecule 
CYP26A1/B1 inhibitor can endogenously increase atRA concentration, and possibly induce 
neuroprotective pathways.  
1.2 Parkinson’s Disease 
 Parkinson’s disease (PD) was first discovered by James Parkinson in 1817 and was later 
diagnosed by the hallmark “shaking palsy” (Obeso et al., 2017). PD is known to be caused by the 
death of dopaminergic neurons in the substantia nigra pars compacta (SNpc) within the basal 
ganglia. Genetic factors are thought to underlie familial PD while sporadic PD is less understood 
and may have environmental underpinnings. Dopaminergic neurons of the SNpc project onto the 
striatum and release dopamine in order to regulate smooth motor movement. Because of cell 
death in the SNpc dopamine signaling is disrupted and PD patients present with motor 
dysfunction such as: tremors, rigidity, bradykinesia, swallowing, and speech difficulties 
(Armstrong & Okun, 2020). Other non-motor dysfunctions such as insomnia, depression, REM 
sleep disorder, and constipation can predate the onset of motor issues as far back as ten years 
(Goldman & Guerra, 2020). Age is a prevalent factor with frequency increasing almost 
exponentially over time, peaking at 80 years old (Driver et al., 2009). Environmental factors such 
as pesticide exposure, TBI, rural living and agricultural occupation, β-blocker use, and well-
water drinking all increase the risk of PD. Interestingly; tobacco smoking, coffee drinking, non-
steroidal anti-inflammatory drug use, calcium channel blocker use, and alcohol consumption all 
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reduce the risk of PD (Noyce et al., 2012). Genetics play a major role in contributing to the 
prevalence of PD. The first gene discovered to be associated with familial inherited PD encodes 
⍺-synuclein (SNCA) (Polymeropoulos, 1997). Leucine rich repeat kinase 2 (LRRK2) is the most 
common cause of dominantly inherited PD while parkin (PARK2) is the most common cause 
behind recessive familial inheritance. (Corti et al., 2011) β-glucocerebrosidase (GBA) was found 
to be the highest genetic risk factor associated with the development of PD (Sidransky & Lopez, 
2012). Taken together, genome wide association studies (GWAS) found single-nucleotide 
polymorphisms within 24 loci, including the genes mentioned above, to be associated with 
developing PD (IPDGC et al, 2014). More than 10 million people are living with PD globally, 
and nearly 1 million Americans are living with PD while 60,000 cases occur annually in the 
USA (Marras et al., 2018).  
1.2.1 Pathology: Lewy Body Formation/Braak Staging 
 Lewy body 
formation within 
the SNpc has been 
the historical 
hallmark of PD 
diagnosis. Lewy 





in the cell body 
(Lewy bodies) or 
neurite (Lewy neurites). Missense mutations of the SNCA gene are associated with autosomal 
PD. Missense mutations can cause a substitution of an amino acid resulting in altered protein 
functions. Additionally, multiplications of the gene locus can result in over transcription. In 
either case the result is SNCA aggregation and the eventual formation of Lewy bodies (Devine et 
al., 2011). Over time, Lewy body formation follows Braak stageing hypothesis. In a caudal-
rostral direction starting in the peripheral nervous system and olfactory nuclei (Stage 1), Lewy 
Figure 1.3: Braak Staging Progression in PD. ⍺-synuclein (SNCA) aggregates into Lewy bodies/neurites beginning in the 
peripheral nervous system (Stage 1), ending in complete innervation of the cerebral cortex (Stage 6). 
Source: Braak et al. (2002), with permission from Spring Nature (lic #: 5118931386497) 
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bodies begin to aggregate and progressively affect the CNS. Next, innervating the pons and 
spinal cord gray matter (Stage 2), and affecting the midbrain, limbic system, and basal forebrain 
(Stage 3). After the limbic system, Lewy bodies can be found within the thalamus and temporal 
cortex (Stage 4), with other aggregates forming across the cortical regions in the final stage 
(Stage 5) (Braak et al., 2003) (Figure 1.3). SNCA aggregation and resulting Lewy body 
formation is thought to cause cell death by mitochondrial and nuclear degradation (Power et al., 
2017). Additionally, Lewy neurites have been attributed to synaptic dysfunction and NT 
deprivation (Schulz-Schaeffer, 2010). Interestingly, SNCA is expressed in the enteric nervous 
system with levels increasing with age. Elevated levels of misfolded SNCA is also observed in 
the intestines of PD patients (Bottner et al., 2012). This may be a factor of the preliminary non-
motor dysfunction surrounding constipation and supports the emerging importance of the gut 
brain axis for PD pathology.  
1.2.2 Prominent Genes 
 While SNCA mutation in PD is considered rare, the identification of Lewy bodies led to 
the discovery of other genes associated with monogenic PD (Corti et al., 2011). The most 
common gene associated with autosomal dominate inherited PD, LRRK2, predominately 
undergoes missense mutation, Gly2019Ser, which causes an increase in kinase activity (Ozelius 
et al., 2006). LRRK2 belongs to the leucine-rich repeat kinase family and is involved in multiple 
cellular processes ranging from neurite outgrowth and membrane trafficking to autophagy and 
protein synthesis (Cookson, 2012; Sanna et al., 2012). Gly2019Ser mutations of LRRK2 gene in 
Drosophila reveal pathogenic effects resulting in targeted dopaminergic neuronal cell loss and 
motor locomotion dysfunction (Liu et al., 2008). Other genes that are associated with autosomal 
recessive PD have been identified as well. Autosomal recessive inherited Parkinsonism is 
associated with early onset PD, before 40 years old (Schrag & Schott, 2006). PARK2 is an E3 
ubiquitin ligase that works in coordination with PTEN-induced putative kinase 1 (PINK1) to 
break down and dispose of damaged or polarized mitochondria. Mutations to these proteins 
causes mitochondrial damage and impaired clearance, oxidative stress, and inappropriate Ca2+ 
signaling. All of these factors contribute to neuronal dysfunction and the cell death leading to PD 
pathology (McCoy & Cookson, 2012). Taken together, the genetic constituents that underlay the 
pathogenesis of PD revolve around protein aggregation, membrane trafficking, 
mitophagy/autophagy systems, and mitochondrial health. Observing genetic and molecular 
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mechanisms involving PD pathogenesis also lead to the use of 6-hydoxyl-dopamine 1-methyl-4-
phenyl-1,2,3,6-tetrahydropyridine (MPTP) as a model for mitochondrial dysfunction (Smeyne & 
Lewis, 2005).  
1.2.3 Inflammation 
 PD is marked by cell death in the SNpc with additional dopamine (DA) signaling 
dysfunction to the striatum. Genetic mutations and environmental factors cause 
neurodegeneration and Lewy body formation with neuroinflammation playing a central role in 
PD pathology. Innate and adaptive immune systems are active in the CNS inflammatory 
response. Although the brain has a “privileged” immune system, CD4+ and CD8+ T-lymphocytes 
are observed in the SNpc of PD patients in addition to MPTP treated mice (Brochard et al., 
2008). Neurodegeneration activates microglia, gliosis, which allows for active signaling of 
neurotrophic factors and cytokines. Important neurotrophic factors such as: BDNF, and glial-
derived neurotrophic factor (GDNF) are released from activated microglia (Batchelor, 2002). 
BNDF and GDNF are well known to be essential for DA neuronal survival. In vivo and in vitro 
models of PD support the neuroprotective effect of these neurotropic factors on DA neurons of 
the SNpc, mediated by activated microglia (Kirschner et al., 1996; Tomac et al., 1995). In stark 
contrast to the beneficial effects of activated microglia, gliosis often results in the release of 
neurotoxins such as: reactive oxygen/nitrogen species (ROS/RNS), tumor necrosis factor-alpha 
(TNF-⍺), and interlukin-1-beta (IL-1β) (Long-Smith et al., 2009). Incorporating 
neuroinflammation into PD pathology is an important aspect when considering treatment and 
therapeutic targets. Targeting the SNpc with neurotropic signaling constituents could save DA 
neurons and the downstream effect on motor control in the nigrostriatal pathway. 
1.2.4 Nigrostriatal Pathway: Parkinsonian Dysfunction 
 The complete understanding of genetic and environmental factors associated with PD are 
still lacking in many areas; however, the pathogenesis of PD does rely on the death of 
dopaminergic neurons in the SNpc and subsequent loss of dopaminergic signaling to the 
striatum. The nigrostriatal pathway is dependent on the homeostasis of the dopaminergic neurons 
within the SNpc and dysregulation of DA signaling can result in loss of motor control. Within 
the basal ganglia the SNpc projects dopaminergic neurons towards the caudate nucleus and 
caudate putamen, together called the striatum. While input to the striatum originates from the 
SNpc and cortex, output from the basal ganglia is directed toward the thalamus via GABAergic 
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neurons from the globus pallidus interna (GPI). The thalamus directs nigrostriatal signaling 
towards the cortex for smooth movement muscle coordination. The cortex projects glutaminergic 
neurons to the striatum, while the striatum projects GABAergic neurons to the GPI and globus 
pallidus externa (GPE). The GPE then projects GABAergic neurons onto the subthalamic 
nucleus, which in turn projects glutaminergic neurons back onto the GPE and GPI. It is 
important to note that the striatal GABAergic neurons which project to the GPI express 
dopamine-1 receptors (DRD1) while striatal neuronal projections to the GPE express dopamine-
2 receptors (DRD2). These striatal 
projections are considered the direct and 
indirect sequence for the nigrostriatal 
pathway, respectively (Figure 1.4). DRD1 
are excitatory receptors while DRD2 
receptors are considered inhibitory. When 
normal DA is present within the striatum, 
the direct pathway takes control of 
inhibitory projection to the GPI, causing 
active signaling through the thalamo-
cortical spinal pathway. PD pathogenesis 
arises when DA neurons of SNpc die due to 
genetic and environmental reasons 
discussed above. Once DA signaling is reduced or absent the excitatory/inhibitory projections 
from the striatum, mediated by DRD1/DRD2 receptors, becomes dysfunctional. Specifically, the 
indirect pathway takes precedence and causes glutaminergic projections from the subthalamic 
nucleus to become active, thus exciting GABAergic projections from GPI onto the Thalamus. 
This dysfunctional excitation of the GPI causes inhibition of thalamic output to the cortex, 
phenotypically observed as dysfunctional smooth muscle movement or “shaking palsy” (Harris 
et al., 2020).  
1.2.5 Current treatments  
 Current interventions for PD are targeted toward treatment of symptoms with the aim of 
improving quality of life. These therapies often target the DA system including receptors and 
transporters. Levodopa, a BBB permeable dopamine precursor is used for severe symptoms of 
Figure 1.4: Nigrostriatal Pathway. The direct pathway is favored during normal 
dopamine release from substantia nigra pars compacta to facilitate smooth muscle 
movement. The indirect pathway is favored during PD pathogenesis due to lack of 
dopamine signaling.  
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bradykinesia. Since dopamine cannot cross the BBB levodopa is administered in coordination 
with carbidopa, a deoxy-carboxylase inhibitor, in order to prevent the peripheral conversion of 
levodopa to its active metabolite, dopamine, before crossing the BBB. Anti-cholinergic drugs 
such as clozapine can be used to treat tremors.  Unfortunately, these drugs have adverse 
reactions. Dopamine agonists and anticholinergic drugs can cause nausea, daytime sleepiness, 
hallucinations, and compulsive behaviors. Long term treatment seeks to balance dopamine 
concentration fluctuations over time by using monoamine oxidase-β inhibitors in coordination 
with other pharmaceuticals (Fox et al., 2011). Treatment of non-motor symptoms associated with 
PD often target depression. Venlafaxine is a serotonin and norepinephrine reuptake inhibitor and 
pramipexole, a dopamine agonist, seem to be effective in treating depression in PD patients 
(Richard et al., 2012; Barone et al., 2010). Interestingly, aged mice have decreased mRNA levels 
of genes necessary for atRA synthesis and metabolism: Lrat, Reh, RALDH2, CYP26A1. 
Treatment of Vitamin A also resorted memory performance and hippocampal neuronal 
morphology, suggesting that all-trans retinoic acid (atRA) signaling is diminished with age 
(Dumetz et al., 2020). Furthermore, studies using retinoic acid receptor (RAR⍺/β) agonists show 
protection of midbrain dopaminergic neurons following lipopolysaccharide (LPS) induced 
toxicity studies. Oral administration of tamibarotene (Am80), an RAR⍺/β agonist, also prevented 
dopaminergic cell loss in the substantia nigra (Katsuki et al., 2009). Together this research points 
toward atRA therapy as a possible mediator of PD pathogenesis. Small molecule CYP26A1/B1 
inhibitors can raise the endogenous levels of atRA in the cell and mitigate the loss of retinoid 
signaling observed in ageing individuals or patients with PD. Additionally, atRA signaling could 
rescue dopaminergic neurons in the SNpc 
from apoptosis and prevent neuronal loss in 
PD patients.  
1.3 All-trans Retinoic Acid 
  1.3.1 Biosynthesis, Transport, & 
Metabolism of Endogenous Retinoids  
 All-trans retinoic acid is an active 
metabolite of Vitamin A (retinol). Retinol is 
a fat-soluble retinoid derived from a diet 
containing provitamin A carotenoids, 
Figure 1.5: Retinoic Acid Biosynthesis Schematic. Vegetables and meats contain the 
source of carotenoids and retinyl esters respectively. Both are used for the biosynthesis 
of retinoic acid. Retinoids are stored as retinyl esters, predominantly in the liver.   
Source: Libein et al. (2017), with permission from Elsevier (lic. #: 5120971023697)  
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primarily β-carotene (D’Ambrosio et al., 2011) (Figure 1.5). Bioconversion of β-carotene into 
retinal primarily occurs in the small intestine enterocyte and is also thought to occur in the liver 
(Tang et al., 2003). Initially β-carotene undergoes symmetric oxidative cleavage at the 15,15’ 
double bond via beta-carotene oxygenase 1 (BCMO1) to form two molecules of retinal. Further 
reduction by retinal reductase (Rrd) forms retinol, the predominate transport retinoid for blood 
circulation (Tang et al., 2003). Due to its hydrophobic nature retinol forms a trimer with retinol-
binding protein 4 (RBP4) and transthyretin (TTR) in a 1:1:1 ratio in order to halt filtration in the 
kidneys (Raghu & Sivakumar, 2004). 
Storage occurs primarily in the liver 
with active conversion of retinol into 
retinyl esters via lecithin:retinol acyl 
transferase (LRAT). Two 
transmembrane receptors, signaling 
receptor and transporter of retinol 
(STRA6) and retinol binding receptor 
protein (RBPR2), can uptake and 
convey extracellular retinol to cellular 
retinol binding protein type 1 
(CRBP1), the intracellular retinol 
carrier protein. At this point 
intracellularly, two separate oxidation 
reactions occur in order to form atRA. 
Starting with holo-CRBP1, retinol is 
oxidized by retinol dehydrogenase 
(RDH) in a protein-protein 
interaction to form retinal, still bound to holo-CRBP1. Depending on RDH subtype this can 
occur in a microsome (RDH1) or lipid droplet (RDH10) within the cell. From there the 
irreversible conversion of retinal into atRA is carried out by retinal dehydrogenase (RALDH1,2,3), 
again in a protein-protein interaction (Napoli, 2020) (Figure 1.6). Once atRA is formed the 
cellular retinoic acid binding protein (CRABP2) transports atRA into the nucleus for atRA 
directed signaling with subsequent retinoic acid receptors (RARs) located on retinoic acid 
Figure 1.6: atRA Biosynthesis, Signaling, & Storage Pathway. Retinol enters cell and is oxidized 
twice to form atRA. RALDH is irreversible oxidation step in atRA synthesis. 
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receptor elements (RAREs) (Napoli, 2017) (Figure 1.7). Degradation of atRA occurs between 
CRABP1 and cytochrome P450 (CYP26A1/B1) enzymes at the surface of the endoplasmic 
reticulum and creates hydroxyl retinoic acid metabolites (Figure 1.6). 
 Several factors influence this system; either driving the pathway forward toward 
biosynthesis of atRA, or in reverse; ending with retinyl ester storage. CRBP1-apo/holo ratio has 
significant control over the activation of LRAT. Where apo-CRBP1 at ~2uM causes LRAT 
inhibition, driving RDH mediated formation of retinal via protein-protein interaction with 
retinol-holo-CRBP1.  A high concentration of apo-CRBP1 drives the atRA biosynthesis pathway 
forward by making retinal available for the irreversible oxidation by RALDH into atRA, while 
also halting the storage of retinol into retinyl esters. In contrast, atRA self regulates its 
intracellular concentration by inducing CYP26s (CYP26A1/B1/C1) and Lrat transcription, 
effectively directing the pathway toward atRA metabolism and retinyl easter storage, 
respectively (Napoli, 2020). Interestingly, retinol and atRA are considered teratogenic and 
exhibit hormesis. Hormesis is characterized by a beneficially effective dosage following an 
upside down “J” curve, where increasing low dosage enters a “goldilocks” zone before additional 
dose increases cause toxicity at high concentrations (Hayes, 2007). For healthy adults atRA 
plasma concentrations are around 2nM with 1uM being the peak concentration for therapeutic 
doses (Jing et al., 2016: Adamson et al., 1995). The biosynthesis, transport, and metabolism of 
retinoids must be highly regulated in order for proper transcription of gene targets.  
1.3.2 atRA Regulation & Canonical Signaling  
After biosynthesis of atRA is 
completed in the cytosol, holo-CRABP2 
moves into the nucleus and directs atRA 
to retinoic acid receptors RAR⍺,β,𝛾 
(RARs) via protein-protein interaction. 
In contrast, CRABP1 does not associate 
with RARs in the nucleus, but instead 
transfers atRA through diffusion 
(Napoli, 2017). atRA signaling takes 
place in the nucleus and is mediated 
through RAR/RXR dimer signaling. 
Figure 1.7: Canonical Retinoic Acid signaling Pathway. 
Source: Pohl & Tomlinson (2020), with permission from Elsevier (lic #: 5132001432519 
)  
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RARs and RXRs belong to the nuclear receptor superfamily and form functional heterodimers 
between each other when atRA is present (Figure 1.7). Additionally, RXR/RXR homodimers can 
form when 9-cis-RA is present. The RAR-RXR nuclear receptors, found at retinoic acid response 
elements (RAREs) on the DNA, undergo conformational change when bound to atRA causing the 
RAR/RXR heterodimer complex to form, releasing the co-repressors, and recruiting co-activators 
(Germain et al., 2006a: Germain et al., 2006b). Classical RAREs are defined by a combination of 
hexametric motifs [(A/G)-G-(G/T)-T-C-A] designated “direct repeats 1-5” (DR1-DR5). These 
repeats are separated by 1, 2, or 5 base pairs (Bastien et al., 2004). Other non-canonical RAREs 
contain sequences with different spacing (DR0, DR8) or inverted repeats (IR0) (Moutier et al., 
2012). This research utilized a GWAS study analyzing RARβ transcriptional target sites in order 
to better understand downstream targets of atRA signaling in neurodegenerative diseases 
(Niewiadomska-Cimicka et al., 2017; 
Supplemental Data, Gene List 1-3). 
Structurally, RAR/RXRs have a 
variable N-terminal domain (AF-1), a 
conserved DNA-binding domain 
(DBD), and a C-terminal ligand-
binding domain (LBD). The LBD 
contains the ligand-dependent 
activation function (AF-2), which 
allows for coregulator interaction. Not 
surprisingly, the LBD also binds to 
atRA for dimerization to occur. The 
AF-1 contains phosphorylation sites 
that can interact with Src-homology-3 
and tryptophan-tryptophan (WW) 
domains (Gronemeyer et al., 2004). 
The DBD contains two zinc binding 
motifs: an N-terminal recognition 
helix, and a DNA stabilizing helix. 
The LBD is organized in an “anti-
Figure 1.8: Crystal Structure RARβ-RXR⍺ Heterodimer. Nuclear receptors bound to DNA, 
ligand (RA), and coactivators. Ligands (yellow spheres), RAR-RXR co-activator binding surface 
(cyan, Helix 12) and dimerization surface (orange), Co-activator peptides (magenta) (PBD, 5UAN).  
Source: Maire et al. (2020), with permission from Elsevier (lic. #:5113781026721) 
 
 16 
parallel ⍺-helical sandwich,” which is comprised of 12 helices (H1-H12). The H12 C-terminal 
helix modulates the binding of transcriptional coactivators in a ligand dependent manner (Chandra 
et al., 2017) (Figure 1.8). 
RAR/RXR heterodimers act as transcriptional activators or repressors depending on the 
presence of atRA. Additionally, inverse agonists can act on RAR/RXR complex to become 
associated with co-repressors. Functionally, co-activators bind to RAR/RXR nuclear receptor 
interacting domains (NRIDs) when atRA is present in the receptor. NRIDs are comprised of three 
to four repeats of LxxLL motifs. Hydrophobic interactions between leucine residues and hydrogen 
bonds formed with RAR/RXR H3/H12 helices account for protein-protein interaction (Figure 1.8). 
NCoA1(steroid receptor co-activator-1) is a well-known co-activator with seven LxxL motifs 
(Spencer at al., 1997). Co-repressor recruitment occurs when atRA is not present and is similar to 
co-activator recruitment with the motif and helices changed. Importantly the H12 helix is not 
involved in co-repressor binding. SMRT and N-Cor (Silencing mediator of retinoic and thyroid 
hormone repressor, Nuclear co-repressor) are well known co-repressors that contain three 
functional LxxI/HIxxxI/L receptor box motifs (CoRNR 1-3). RAR/RXR H3/H4 helices form a 
hydrophobic surface which allows for CoRNR docking.  After docking, confirmational changes 
create an antiparallel β-sheet between the proteins at the N-terminus further strengthening the co-
repressor interaction. (le Maire et al., 2010) In general, coactivators acetylate histones while 
corepressors recruit histone deacetylases (HDACs) (Heinzel et al., 1997: Nagy et al., 1997). In 
effect, co-activators and repressors act to relax or condense chromatin allowing for transcription 
or repression of regulated genes downstream. Once atRA is bound to the RAR/RXR/RARE 
complex co-repressors are released and co-activators are recruited followed by histone acetylation 
which relaxes the chromatin while RNA polymerase II is recruited for transcription of target genes. 
After transcription signaling is achieved RAR/RXR is ubiquitinated for degradation via a 
proteasome (Kopf et al., 2000). This dynamic system allows for atRA to act as signaling molecule 
for downstream regulation of target genes.  
1.3.3 Non-Canonical atRA signaling 
 Past research has uncovered ~15,000 potential RAREs through RAR chromatin 
immunoprecipitation coupled sequencing (Delacroix et al., 2010; Mahony et al., 2011; Marten et 
al., 2010; Mendoza et al., 2011; Ross-Innes et al., 2010). Other genome-wide association studies 
(GWAS) identified RAR/RXR regulated genes (Al Tanoury et al., 2014; Fang et al., 2013; 
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Penvose et al., 2019; Niewiadomska-Cimicka et al., 2017). These sites should follow canonical 
gene regulation by atRA as mentioned in section above. In contrast, the non-canonical gene 
regulation by atRA is not mediated by RAR/RXR guided transcription but instead utilizes the 
CRABP1 carrier protein to modulate mitogen-activated protein kinase (MAPK) signaling (Park 
et al.,2019a).  
 In the presence of growth factors MAPK signaling pathway utilizes RAF-MEK-ERK 
cascade for cell growth and proliferation. In the absence of growth factor stimulation holo-
CRABP1 interacts directly with rapidly accelerated fibrosarcoma kinase (RAF) to serve as a 
signal scaffold, conveying RAF to MEK and ERK, resulting in ERK1/2 phosphorylation. 
Interestingly, this also occurs under a rapid time dependent manner, peak 15 minutes, in a non-
genomic fashion. Conversely, holo-CRABP1 in the presence of growth factors can act as a 
competitive agonist compared to RAS binding with RAF. Taken together, holo-CRABP1 can act 
as a modulator of MAPK 
signaling in a growth factor 
dependent manner (Park et al., 
2019a) (Figure 1.9). CRABP1 
also plays a non-canonical 
regulatory role in 
cardiomyocytes when bound 
to atRA. In the presence 
elevated intracellular calcium 
or isoproterenol stimulation 
Ca2+/calmodulin (CaM) binds 
to CaMKII causing 
autophosphorylation of T287 and autonomous kinase activity. CaMKII then goes onto 
phosphorylate ryanodine receptor (RyR2) on the sarcoplasmic reticulum for endogenous Ca2+ 
release. Holo-CRABP1 inhibits CaM autophosphorylation and therefore dampens the Ca2+ 
release response when atRA is present. This in turn protects against overexcitation in 
cardiomyocytes (Park et al., 2019b). These non-canonical atRA signaling pathways provide new 
therapeutic models for retinoid therapy and may be applied to the excitotoxity following TBI. 
 
Figure 1.9: MAPK Signaling Pathway Under Retinoic Acid & Growth Factor Stimulation. Canonical 
MAPK signaling in the presence of growth factor (Left). Non-canonical MAPK signaling directed by retinoic 
acid when growth factor is absent (Center). RA mediated dampening of MAPK signaling as competitive agonist 
to Ras binding domain (Right).  
Source: Park et al. (2019a), Springer Nature Open Access.  
 
 18 
1.3.4 Retinoic acid in the Adult Brain 
 Identification of RALDH expression found that stable RA synthesis in the postnatal brain 
mainly occurs in the basal ganglia, hippocampus and auditory afferents in the adult brain 
(Wagner et al., 2002). Additionally, RALDH1 is expressed throughout blood vessels in the brain 
while RALDH2 is found primarily in the olfactory bulb, where adult neurogenesis can occur. In 
coordination with possible RA synthesis in these areas, RAREs were identified in limbic 
structures, dorsal horn of spinal cord, and periglomerular layers of the olfactory bulb (Thompson 
et al., 2002). RAR receptor expression is diverse across the adult brain with RAR⍺ being 
relatively highly expressed within the hippocampus and cortex. Interestingly, RARβ is fairly 
localized to the caudate putamen and nucleus accumbens and is more highly expressed than 
RAR𝛾 (Krezel et al., 1999). RARβ and RARβ/𝛾 knock out mice show a loss of CA1 region in 
the hippocampus and have reduced long-term potentiation (LTP) and long-term depression 
(LTD) (Chiang et al., 1998). atRA can act as a natural regulator of DRD2 receptors in 
developing primary striatal neurons in rats through RARE directed signaling (Valdenaire et al., 
2002). This is important because DRD2 null mutation mice present with Parkinson-like motor-
locomotion phenotype (Fowler et al., 2002). Additionally, RALDH1 is specifically expressed in 
substantia nigra neurons which synapse on the striatum (McCaffery & Drager, 1994). This is 
interesting because RA signaling and RALDH expression decreases with age, supporting a 
possible role for RA signaling in memory (Dumetz et al., 2020). Taken together the expression 
of atRA synthesis machinery with RARs/RAREs suggest that atRA signaling is an important 
factor in the regulation of neurogenesis, locomotion, memory, and learning in the adult brain. 
The possibility of atRA signaling rescuing dopaminergic neurons and DRD2 signaling between 










2. CYP26A1/B1 & DX308 Modeling Investigations 
  2.1 Cytochrome P450: CYP26A1/B1 
 CYP26A1 and CYP26B1 belong to the cytochrome P450 superfamily of heme-
containing enzymes. Cytochrome P450 
enzymes are primarily located in the 
membrane of the endoplasmic reticulum 
within liver, intestine, lung, kidney, and 
brain tissue (Ding & Kaminsky, 2003). 
Fifty-seven P450 enzymes within 
humans are responsible for the oxidation 
and reduction of most drugs used today, 
with the predominate isoforms identified 
to be: CYP1A1/A2, 
CYP2B6/C8/C9/C19/D6/E1, and 
CYP3A4/A5 (Guengrich, 2005). Other isoforms involved in homeostatic maintenance involve: 
CYP4B1/F2/F12. CYP17A1, CYP19A1, CYP26A1/B1/C1. Catalytic activity requires electron 
donations from NADPH with additional redox constituents, cytochrome P450 reductase and 
cytochrome b5, to aid in the electron transfer (Schenkman & Jansson, 1999). Because of 
cytochrome P450 extensive mediation of drug metabolism and homeostatic functions, these 
enzymes are a primary target for therapeutic drug intervention. Retinoic acid metabolizing 
blocking agents (RAMBAs) inhibit cytochrome P450s through type II interaction which involves 
an sp2 hybridized nitrogen for heme iron coordination (Schenknman & Jansson, 2006).  
 CYP26A1/B1/C1 are the predominate cytochrome P450 enzymes responsible for the 
oxidative metabolism of atRA. CYP26A1/B1 are expressed at low levels in most tissues of the 
adult human brain with the highest levels of expression observed in the pons and cerebellum 
(White et al., 2000). A more recent study involving the rat brain has found CYP26B1 expression 
within the striatum (Stoney et al., 2016). Together, the general expression of atRA metabolizing 
CYP26 enzymes throughout the brain with specialization occurring in the pons, cerebellum, and 
possibly striatum supports the homeostatic function of retinoid signaling in the brain. Targeted 
inhibition of CYP26A1/B1 enzymes with the specific purpose of increasing endogenous atRA 
concentration is the primary focus of this research. Modeling began with the comparisons of both 
Table 2.1: Novel RAMBA Library. CYP26A1/B1 IC50 values for comparison of selective 
inhibitor. Special interest for structure DX308 (2) for having equal inhibition of 
CYP26A1(IC50=0.05 uM) and CYP26B1 (IC50=0.05uM). 
 
CdId Structure MW Formula ID_Struc CYP26A1 IC50 uM CYP26B1 IC50 uM A1/B1
1 398.50 C27H26O3 CD437
0.04 0.03 1.34
2 405.54 C26H31NO3 DX0308
0.05 0.05 1
3 412.53 C28H28O3 CD271
0.12 0.17 0.68
4 391.51 C25H29NO3 DX0314
1.75 0.11 16.22
5 398.50 C27H26O3 CD1530
0.53 0.8 0.65
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atRA and major metabolites with a known RAMBA (R116010) and previously modeled 
xenobiotic substrate, tazarotenic acid. Previous research carried out in the Diaz lab positively 
identified CYPP26A1/B1 inhibitors with repeated IC50 assays (*data unpublished). IC50 assays 
were carried out by expressing CYP26A1/B1 in SF9 cells and preparing microsomal fractions. 
100nM 9-cis-RA was used as the substrate and formation of the metabolite 9-cis-OH-RA was 
measured by HPLC. Following positive identification of CYP26 inhibitors further examination 
of a novel Diaz compound, DX308, was used in parallel comparison to previously known 
RAMBAs (Table 2.1). 
2.2 Experimental Approach: Docking of DX308 in CYP26A1/B1 Homology 
Models 
 DX308 has been shown to inhibit CYP26A1/B1 but no experiments have been performed 
to show that DX308 binds to the active site of CYP26A1/B1. Our hypothesis is that DX308 bind 
in a similar way to natural or synthetic retinoids such as atRA and tazarotenic acid. We decided 
to use CYP26A1 and B1 homology models based on previous published work (Foti et al., 2016) 
to demonstrate that DX308 is a competitive CYP26 inhibitor mimicking retinoid structure 
binding modes.  
 Since neither CYP26A1 nor CYP26B1 has been isolated for Xray-crystallography, 
homologs were used from previous research carried out by Foti et al., 2016 and Foti, Diaz & 
Douguet 2016. In 2016, the homology models of CYP26A1/B1 were constructed using Prime 
(Schrödinger LLC, New York, NY). Both amino acid sequences of human CYP26A1/B1 were 
sourced from NCBI protein server (Gene ID: 1592/56603). The crystalized structure of CYP120 
(pdb: 2VE3) was used as a template to create both homology models. CYP26A1/B1 had 
33%/34% sequence identity and 53%/54% positive sequence coverage respectively. The heme 
prosthetic group was ligated to Cys 442 and Cys 441 of CYP26A1 and CYP26B1 respectively. 
Energy minimalization was carried out with OPLS_2005 and force-field constraints were defined 
within the MacroModel algorithm (Schrödinger). The homology model was structurally 
rationalized by evaluating Ramachandran plots and odd bond lengths and angles via PSIPRED 
(university College London, UK). SSPro (Schrödinger) software allowed for comparison of 
helical loop motifs and two-degrees-of-freedom structure characteristics to determine model 
flexibility. Once the homology models were created, the protein data bank (.pdb) files were used 
in the Foti et al., 2016a publication to identify Tazarotenic acid as a xenobiotic substrate of 
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CYP26A1/B1. Additionally, the .pdb files were used in the Foti, Diaz & Douguet 2016 
publication to model ketoconazole and R115866. For the purposes of the current 2020-2021 
research project the .pdb files were again used to compare novel CYP26A1/B1 inhibitor, DX308, 
against known CYP26 inhibitors; R116010, and the previous xenobiotic substrate, tazarotenic 
acid (Supp. Data, CYP26A1, CYP26B1 .pdb files). Both .pdb files underwent a BLAST 
sequence search in NCBI to confirm that we were working with 100% human CYP26A1/B1 
enzymes. After confirmation, the .pdb files were used in Flare V3.0 modeling software for all 
ligand comparisons. All ligands were created in Flare V3.0 modeling software in addition to 
energy minimalization and ligand-protein docking. The docking grid was set up in an identical 
fashion to Foti et al., 2016a paper; where the center of the grid was placed 2-3 Å above the heme 
iron, with a 12 x 12 x 12 Å grid constructed around the center. Initial docking of atRA and major 
metabolites, 4-OH-RA and 16-OH-RA, compared active residues with previous modeling carried 
out by Foti et al., 2016. Further docking of Tazarotenic acid, R116010, and DX308 was 
performed in order to observe and compare active residues between the different modeling 
software. These modeling investigations indented to support DX308 as a novel RAMBA by 
showing similarities to the binding conformations of tazarotenic acid, R116010, and atRA 





2.3 atRA substrate & Metabolite Comparison Results 
 Initial modeling investigations with the Flare V3.0 software overwhelmingly supported 
previous model docking poses observed with GlideScore and eModel (Schrödinger; Foti et al., 
2016a). The primary residues involved with protein ligand interaction for atRA, 4-, and 16-OH 
metabolites had almost identical overlap. Trp 112, Phe 222, Phe 299, Arg 90 residues were 
active in the CYP26A1 binding pocket. This corresponds to Trp 117, Phe 222, Phe 295, Arg 95, 
Trp 65 within CYP26B1. With respect to previous modeling; Arg 90 (CYP26A1) and Arg 95, 
Trp 65, and Tyr 372 (CYP26B1), are all overlapping active residues that orient the carboxylic 
tail of atRA and the major metabolites within the 3.0 Å distance previously observed. This is also 
further supported by residues that orient hydrophobic the β-ionone ring toward the heme; Trp 
112, Phe 222, Phe 299 (CYP26A1) and Trp117, Phe 222, Phe 295 (CYP26B1). Foti et al., 2016 
also reported that 4-OH metabolite is metabolically unfavorable compared to 16-OH. This was 
proposed due to the measurements made between the hydrogens at 4-, 16- position of atRA 
relative to heme iron. Our research found similar results with 4-OH-RA to be 5.6 Å (CYP26A1) 
and 6.5 Å (CYP26B1) compared to 5.59 Å and 4.06 Å observed by Foti et al; while 16-OH-RA 
is closer to the heme iron at 3.9 Å for both CYP26A1/B1, supporting Foti et al., observations of 
3.9 Å/2.9 Å for CYP26A1/B1 respectively. (Table 2.2, Figure 2.1) Taken together, these 
measurements support the previously observed ligand orientation relative to the active residues 
Figure 2.1: Molecular Modeling of CYP26A1/B1-atRA/Metabolites. CYP26A1/B1 ARG90/95 <3 Å away from carboxylic moiety. atRA 
metabolite favors 16-OH-RA with respect to distance from heme to active carbon (4-OH-RA: 5.6/6.5 Å vs. 16-OH-RA 3.9 Å). Distances 
consistent with Foti et al. (2016a). A) CYP26A1 bound atRA vs. 4-OH-RA metabolite. B) CYP26A1bound atRA vs. 16-OH-RA metabolite. 
C) CYP26B1 bound atRA vs. 4-OH-RA metabolite. D) CYP26B1bound atRA vs. 16-OH-RA metabolite.  
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within the binding pocket. Further support is warranted due to overlapping distances between 
specific target residues controlling carboxylic and β-ionone/heme ring orientation. These results 
are relatively significant since the docking software was different between both experiments, 
only sharing the original .pdb files and docking grid constraints. Further docking of previously 
investigated tazarotenic acid, a RAMBA, and DX308 should continue to support the viability of 
synthetic retinoid docking with CYP26A1/B1 enzymes.  
2.4 Tazarotenic Acid, R116010, & DX308 Comparison Results 
 Modeling of Tazarotenic acid in comparison to Foti et al., 2016a further supported ligand 
docking orientation with respect to CYP26A1/B1 binding pocket described above. Overlap of 
active residues between both investigations include: Arg 90, Trp 112, Phe 222, Thr 304, Gly 372, 
and Pro 478 for CYP26A1; while active residues for CYP26B1 include: Arg 95, Trp 117, Phe 
222, Phe 295, Tyr 372, and Trp 65. Relative distance from the sulfur atom of the 
benzothiopyranyl ring and the heme iron were found to be 5.5/5.9 Å compared to previously 
reported 4.21/4.07-4.11 Å for CYP26A1/B1 respectively. While these distances are >1 Å both 
models report hydrogen bonding interactions between the carboxylic moiety and pyridinyl 
nitrogen with Arg 90 and Gly 372 of CYP26A1 respectively. (Figure 2.2, Table 2.2) Together 
this docking orientation overlap supports using the homology model as a rough assessment for 
RAMBA docking.  
Figure 2.2: Molecular Modeling CYP26A1/B1-Tazarotenic Acid. Tazarotenic bound to CYP26A1/B1 in similar fashion to Foti et al (2016a) 
with carboxylic moiety <3 Å from ARG90/95 residue and benzothiopyranyl ring oriented toward heme iron for formation of tazarotenic acid 
sulfoxide. A) CYP26A1 bound to tazarotenic acid. B) CYP26B1 bound to tazarotenic acid. 
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 R116010 was used 
by Armstrong et al., 2007 
for targeting retinoic acid 
metabolism in SHSY5Y 
neuroblastoma cell line. Our 
research intended to mimic 
the cell culturing experiment 
with a novel RAMBA, 
DX308. For this reason, 
R116010 compound was 
used in CYP26A1/B1 
docking investigations to 
further support ligand 
orientation for the homology 
models. Specific interest 
was taken to observe similar 
active residues found to be 
necessary for Tazarotenic 
acid orientation. In 
coordination with active 
CYP26A1 residues we 
observed Pi- interactions 
between Trp 112/Phe 222 
and the aromatic moieties of 
both ligands, R116010 and 
Tazarotenic acid. 
Corresponding CYP26B1 
residues include: Trp 117, Phe 222, and Trp 65. Additionally, work carried out by Foti, Diaz & 
Douget 2016b docking ketoconazole and R115866 places the sp2 hybridized nitrogen within the 
imidazole ring < 3 Å away from the heme iron. Our modeling observations of R116010 docking 
also shows imidazole orientation toward the heme iron at < 3 Å, supporting an active type II 
Figure 2.3: Molecular Modeling CYP26A1/B1-R116010. RAMBA used in SHSY5Y atRA response experiments 
carried out by Armstrong et al. (2007) JML_135 modeled same cell line with different RAMBA, DX308. Ligand 
has loss of carboxylic orientation, gain of type II azole-heme interaction with 3-N-Heme distance <3 Å.  A) 
CYP26A1 bound to R116010. B) CYP26B1 bound to R116010.  
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binding interactions previously observed. (Figure 2.3, Table 2.2) Comparisons of active residue 
location with ligand orientation supports a heme-oriented imidazole with aromatic interactions 
stabilizing the rest of the molecule. Comparisons with DX308 were intended to further support 
this orientation and add information on the heme interactions which could possibly take place on 
the sp2 hybridized oxygen within the attached methoxy.  
 DX308, our novel CYP26A1/B1 inhibitor, had similar binding orientation with respect to 
all other molecules observed. 
Interestingly DX308 incorporated a 
diverse set of residues compared to 
atRA, Tazarotenic acid, and R116010 
alone. Active residues include: Thr 
304, Trp 112, Phe 222, Pro 478, and 
Arg 90 for CYP26A1. Corresponding 
residues in CYP26B1 include: Arg 95, 
Trp 65, Tyr 372, and Ser 369 with Phe 
295 and Trp 117 coordinating the 
hydrophobic adamantly group. DX308 
utilizes Arg 90/ Arg 95 hydrogen 
interactions with the carboxylic moiety 
similar to atRA, metabolites, and 
R116010. Additionally, Pi- interactions 
between aromatic moieties with Phe 
222, Trp 112, Trp 117 all support bulk 
hydrophobic orientation toward the 
heme group. Finally, measurements 
between the heme iron and sp2 
hybridized oxygen attached to 
benzo/adamantyl moiety is 4.0 Å/4.4 Å 
for CYP26A1/B1 enzymes 
respectively. While this is > 3 Å 
reported by Foti, Diaz & Douget 
Figure 2.4: Molecular Modeling CYP26A1/B1-DX308. DX308 bound to CYP26A1/B1 contains 
multiple interactions with active residues found across previous ligands. Carboxylic moiety orients 
toward ARG90/95 with a distance < 3 Å, hydrophobic benzo-adamantyl moiety oriented toward 




(2016) it does allow the possibility for type II binding interactions previously modeled and 
reported. Together DX308 is a viable candidate for inhibition of CYP26A1/B1 enzymes; 
furthermore, particular interest has been noted for specific analogs which allow for previously 
reported orientation. These include the attached adamantyl, methoxy, and butyric acid analogs 
needed for hydrophobic/heme orientation and carboxylic acid interactions. Generally, modeling 
investigations supported previous research and these homology models are an initial step in 
understanding the feasibility for current and future selective CYP26A1/B1 RAMBAs.  
 Our modeling experiments demonstrate that DX308 binds to the active site of CYP26A1 
and CYP26B1 and has a similar binding mode to Tazarotenic acid and atRA forming interaction 
between the carboxylic acid of DX308 and residues Arg95, TYR372 and TRP65 in CYP26B1 
and ARG90 in CYP26A1. These interactions are not found for R116010. Hence DX308 





















Substrate Residue Distance Residue Distance CYP26A1 CYP26B1
atRA ARG 90 2-5 A ̊ ARG 95 2.4-4.9 A ̊ < 3.0  A ̊ < 3.0  A ̊
4-OH-RA ARG 90 2-5 A ̊ ARG 95 2.4-4.9 A ̊
HEME-Fe 5.6 A ̊ HEME-Fe 6.5 A ̊ 5.59 A ̊ 4.06 A ̊
16-OH-RA ARG 90 2-5 A ̊ ARG 95 2.4-3.4 A ̊
HEME-Fe 3.9 A ̊ HEME-Fe 3.9 A ̊ 3.9 A ̊ 2.99  A ̊
Tazarotenic Acid PHE 299 4.4 A ̊ PHE 295 3.0 A ̊
PHE 222 3.5 A ̊ PHE 222 4.9 A ̊
ARG 90 2.4-4.8 A ̊ ARG 95 2.7-3.7 A ̊
TRP 112 3.2 A ̊ TRP 117 (4.4) A ̊
GLY 372 2.7 A ̊ TYR 372 2.0 A ̊
HEME-Fe 5.5 A ̊ TRP 65 1.9-3.7 A ̊
HEME-Fe 5.9 A ̊ 4.21  A ̊ 4.07-4.11  A ̊
R116010 PHE 299 4.8 A ̊ PHE 295 3.5 A ̊
PHE 222 3.6-9 A ̊ PHE 222 4.4 A ̊
TRP 112 4.8 A ̊ TRP 117 3.1 A ̊
GLY 372 3.9 A ̊ THR 372 2.9 A ̊
HEME-Fe 2.3 A ̊ TRP 65 2.7 A ̊
HEME-Fe 2.3 A ̊
DX308 PHE 299 (4) A ̊ PHE 295 3.4 A ̊
PHE 222 3.4 A ̊ PHE 222 4.3 A ̊
ARG 90 1.8-3.7 A ̊ ARG 95 2.1-4.1 A ̊
TRP 112 (4.1) A ̊ TRP 117 (3.4-5) A ̊
THR 304 3.0 A ̊ TRP 65 1.8 A ̊
HEME-Fe 4.0 A ̊ SER 369 2.8 A ̊
TYR 372 2.2 A ̊
HEME-Fe 4.4 A ̊
CYP26A1 CYP26B1 Foti/Diaz Model
Table 2.2: CYP26A1/B1 Modeling Measurements. Modeling software Flare compared to previous work with GlideScore and 
eModel software (Schrödinger). Respective distances for active residues used to support DX308 active binding and inhibition of 
CYP26A1/B1 enzymes via type II interaction.  
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 These studies are intended to be preliminary investigations into the effects of DX308 as a 
novel RAMBA, primarily targeting CYP26A1/B1 atRA metabolism within the central nervous 
system. Previous research had selected the compound from a library of positively identified 
CYP26-inhbitors (Table 2.1). Further in vivo studies looked at DX308 active reduction of TBI 
pathology in a murine model. The purpose of this research is to test DX308 potentiation of an 
atRA response in order to mimic current retinoid-based therapies. This study defines an atRA 
response as a significant increase in gene transcription of CYP26A1 as a factor of endogenous 
atRA signaling (Zolfaghari, et al., 2020). RAR⍺,β,𝛾 are also used as a positive identification for 
active RARE signaling of prospective genetic targets (Pohl et al., 2020). Our hypothesis is that 
DX308 will competitively inhibit the degradation of atRA at endogenous concentration by 
CYP26A1/B1 in neuronal and glial cell line models.  The Aim were 1) to assess the expression 
of CYP26A1 and CYP26B1 in SNB19 and SHSY5Y cells; 2) to characterize the effect of 
retinoic acid signaling activation on these two CYP26s; 3) to demonstrate that cotreatment of 
these cell lines with DX308 and a nanomolar concentration of RA similar to endogenous 
concentration will result in an increase of atRA signaling activation using CYP26A1 as a marker 
of direct RAR activation and CYP26B1 indirect activation; 4) to assess the effect of DX308 on 
the differentiation of SHSY5Y cells, 
  Effective potentiation of atRA via DX308 is defined within the context of an active 
RAMBA. In order for a RAMBA to be considered active; co-treatments of DX308 with low 
doses of atRA (1nM)   create the same, or increased, atRA response as a high dose atRA 
treatment (1uM) alone compared to control. Observations of identical atRA doses will result in 
increased atRA response in the presence of a RAMBA. Additionally, RAMBA treatments alone 
Table 3.1: Experimental Summary. SHSY5YDiff undergoes 10uM atRA treatment day 0-3, followed by 80nM TPA treatment from day 3-6 (atRA/TPA regiment). 
SHSY5YDiffDX undergoes the same atRA/TPA differentiation regiment (reg.) with additional 1uM DX308 24hr treatment for a total of 7 days before harvest. 
 
Experiment # Type Of Cell Used Tretments Genes Panel
jml_101 SNB-19 0.1% DMSO: 1uM atRA: 1nM atRA 36B4, CYP26A1, CYP26B1, RARa, RARb, RARg
jml_111 SNB-19 0.1% DMSO: 1uM atRA: 1nM atRA: 100nM DX308: 1nM atRA + 100nM DX308: 10nM atRA: 10nM atRA + 10nM DX308 36B4, CYP26A1, CYP26B1, RARa, RARb, RARg
jml_127 SHSY5Y 0.1% DMSO: 100nM atRA: 10nM atRA: 1uM DX308: 100nM atRA + 1uM DX308: 10nM atRA + 1uM DX308 36B4, CYP26A1, CYP26B1, CRABP2, RARb, DRD2
jml_135 SHSY5Y+ SHSYDiff 0.1% DMSO: 10uM atRA + 80nM TPA (regiment) 36B4, CYP26A1, CYP26B1, DRD1, DRD2, DRD3
jml_141 SHSY5Y + SHSYDiff + SHSYDiffDX 0.1% DMSO: atRA/TPA: atRA/TPA + 1uM DX308 36B4, CYP26A1, CYP26B1, DRD1, DRD2, DRD3
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will not have an effect on atRA response. Taken together, a RAMBA treatment alone will not 
activate the atRA response, but under co-treatment with atRA exhibit an increase in active atRA 
response, indicating effective RAMBA inhibition of atRA metabolism.  
This study used two human derived cell lines; neuroblastoma (SHSY5Y), and dendritic 
glioblastoma (SNB19). Additionally, a differentiated dopaminergic neuroblastoma 
(SHSY5YDiff); defined by significant increase in dopamine receptor expression relative to 
control, was treated. In total “three” cell lines were treated in this experiment in order to roughly 
model in vivo neuronal and glial populations. Special investigations into differentiation of the 
dopaminergic neuroblastoma cell line are intended to generally model dopaminergic neurons, 
with respect to the Parkinson’s model (Hong-Rong et al., 2010). These cell lines were used for a 
preliminary investigation of DX308 as a selective CYP26A1/B1 inhibitor within the central 
nervous system. One overall study with five independent cell culturing experiments using two 
cell lines was carried out culminating in the gene expression analysis of atRA response across 
various DX308 and atRA treatments (Table 3.1).  
3.2 Methods 
  3.2.1 SNB19-Human Glioblastoma 
 SNB19 (ATCC® CDL-2219™) is a malignant glioblastoma cell line, sourced from a 47-
year-old male’s left parieto-occipital glioblastoma multiforme tumor in 1980. This cell line 
expresses glial fibrillary acidic protein (GFAP) which acts as positive glial marker. DNA 
profiling studies have shown the cell line to be a derivative of U-373 cell line (ATCC® HTB-
17™) which also shares derivative chromosomes with U-373 MG.  
  3.2.1.1 SNB19-Cell Culture 
  The cell line was received when split during passage 19 (P19) from the Bridges Lab, 
University of Montana. The initial cell culture was grown to confluence of ~60% and seven 
cryovials, with 1.5 million cells/vial, were stored in liquid nitrogen for future experiments. All 
cell culture experiments were plated at P20 or higher. All culture media (cDMEM) contained: 
DMEM/F-12 (1:1) +2.50mM L-Glutamine -HEPES (HyClone™, SH30271.01), 10% heat 
inactivated fetal bovine serum (HyClone™, AD1811280), 1% penicillin/streptomycin (Pen/Strep 
Corning™, 30.00CL).  Cells were taken out of cryo-storage and seeded in 75cm2 (T75) culture 
flask at 50,000 cells/mL, 15mL total. cDMEM media was changed every 3-4 days until 60-70% 
confluent. After respective confluency was reached cells were trypsinized (0.025% 
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trypsin/0.01%EDTA, Gibco®, R-001-100), neutralized (Trypsin Neutralizer Solution 1x, Gibco®, 
R-002-100), and counted with Countess® II Automated Cell Counter. Cells are then plated on 12-
well plate (Cellstar®, 665-180) at 200,000 cells/mL with 1mL/well. After 24-48hrs cells were 
~70% confluent and received 24hr treatments for each well in biological triplicates. All 
treatments, including controls, last 24hrs with 0.1%DMSO acting as vehicle control throughout 
all experiments (Table 3.1, Figure 3.2, Figure 3.3). Preparation of atRA and other photosensitive 
compounds were made the day of treatments, with a 20mM working stock saved in a -40oC 
freezer. 
3.2.2 SHSY5Y-Neuroblastoma 
 SHSY5Y (ATCC® CRL-2266™) is a neuroblastoma cell line sourced from a four-year-
old female’s bone marrow. The original metastatic bone tumor biopsy comprised of SK-N-SH 
(ATCC® HTB-11™) cells and was subcloned three times: initially to SH-SY, followed by SH-
SY5, and finally to SH-SY5Y in 1970. Importantly SHSY5Y cell cultures contain adherent and 
non-adherent cells and can be differentiated under specific treatment regiments into mature 
neuron-like phenotypes (Kovalevich & Langford, 2013).  
       3.2.2.1 SHSY5Y-Cell Culture 
 The cell line was thawed from cryo-storage in liquid nitrogen after previous studies 
conducted by Dr. Joachim Veit in January 2018 at passage 8 (P8). The Cryovial was thawed in 
cDMEM media, DMEM/F-12 (1:1) +2.50mM L-Glutamine -HEPES (HyClone™, SH30271.01), 
10% heat inactivated fetal bovine serum (H.I. FBS) (HyClone™, AD1811280), 1% 
penicillin/streptomycin (Pen/Strep Corning™, 30.00CL), and grown to ~70% confluency in a 
T75 flask before freezing multiple vials for storage and future experiments. Freezing media 
contained: 90% H.I. FBS (HyClone™, AD1811280), 10% DMSO (Fisher BioReagents™, 
BP231-100).  
 After growing to ~70% confluency in T75 flask adherent and non-adherent cells are 
trypsinized, neutralized, and plated in 12-well plate. An initial experiment with undifferentiated 
SHSY5Y cells (SHSY5Y) was seeded at 200,000 cell/mL with 1mL/well. After 24-48hrs cells 
were ~70% confluent and received 24hr treatments for each well in biological triplicates. 
Treatments last 24hrs with 0.1%DMSO acting as vehicle control throughout all experiments 
(Table 3.1, Figure 3.4). 
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 Following the initial 
investigations of SHSY5Y cell line; a 
differentiation protocol following 
Presgraves et al., 2004 was followed 
in order for “SHSY5YDiff cells to 
exhibit characteristics consistent with 
cultured dopaminergic neurons”. 
After growing to ~70% confluency in 
T75 flask adherent and non-adherent 
cells were trypsinized, neutralized, 
and plated in 12-well plate at 100,000 
cells/ml with 1ml/well. The control 
treatment group was plated in 0.1% 
DMSO cDMEM media for 7 days, with fresh media changed on day 3. SHSY5YDiff cells were 
plated in 10uM atRA cDMEM media, this media was changed to 80nM 12-O-tetradecanoyl-
phorbol-13-acetate (TPA) on day 3. All cells were harvested on day 7 for RNA extraction and 
qPCR analysis, with special interest on increased dopamine receptor (DRD1,2,3) expression with 
multiple comparisons (Table 3.1, Figure 3.1-Exp. 1, Figure 3.5).  
 The final investigation using SHSY5Y cells involved comparisons between SHSY5Y 
cells and SHSY5YDiff cells with respect to atRA response and DRD1,2,3 expression. Following 
the initial experiment, cells were grown to confluency and plated in a 12-well plate at 20,000 
cells/well with 1mL/well. Control and SHSY5YDiff cells were treated over a 6-day period as 
previously mentioned, with an additional media change on day 6, 24hrs before harvest. A third 
treatment group was grown in the same respect as SHSY5YDiff cells with an additional 24hr 
1uM DX308 cDMEM media treatment (Table 3.1, Figure 3.1, Exp. 2, Figure 3.6). It should be 
noted that this media only contained 1uM DX308 cDMEM media without TPA.  
3.2.3 Differential Gene Expression 
   3.2.3.1 RNA Isolation 
 After respective treatment times cells were harvested using the Qiagen RNeasy® Mini Kit 
(Qiagen, 74106). Supernatant was collected and centrifuged for later investigations. Cells were 
lysed using 600uL of RLT lysis buffer (Qiagen, 1015762) in their 12-well plates for 5 minutes 
Figure 3.1: SHSY5Y Differentiation Regiment. A) Experiment 1, only atRA/TPA regiment. B) 
Experiment 2, follows atRA/TPA regiment with additional solo-DX308 treatment (red star) or solo 
TPA treatment 24hrs before harvest.  
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on a plate shaker. Cell lysate was then mixed with equal part 70% EtOH/ 30% DEPC H2O 
(Ethanol: Deacon Labs, 3961EA) (DEPC H2O: Fisher BioReagents, BP561-1). The lysate 
ethanol cell mix was then loaded and washed on a RNeasy spin column (Qiagen, 1112543) with 
RW1 (Qiagen, 1015763) and RPE (Qiagen, 1018013) wash buffers used respectively. Finally, 
the column was eluted with 40uL of DEPC H2O in a clean collection tube (Qiagen, 1017981). 
Purified RNA was stored in -20oC freezer until reverse transcription can be performed.  
   3.2.3.2 RT-qPCR 
 Purity and concentration of isolated RNA was measured using NanoDrop 2000c (Thermo 
Scientific). cDNA microtubes (Thermo Scientific, AB-0784) were loaded with DEPC H2O 
(Fisher BioReagents, BP561-1), purified RNA, and an iScript cDNA Synthesis Kit (Bio-Rad, 
1708891). The iScript Kit mix comprised of 5x iScript reaction mix (1708889) and iScript 
Reverse Transcriptase (LOO7877B), with 4uL and 1uL per cDNA microtube respectively. RNA 
concentration was normalized to 25ng/uL with Vf=20uL prior to reverse transcription, 500ng 
total. After loading, cDNA tubes were moved into a thermocycler (Bio-Rad, MyCycler ™ 
Version 1.065) for reverse transcription. Following an iScript protocol (activation: 5min/25oC, 
20min/46 oC, 1min/95 oC, hold/4 oC) for reverse transcription. After reverse transcription cDNA 
was kept at -20oC in a freezer until qPCR can be performed.  
For qPCR the cDNA was diluted 1:2 with DEPC H2O for a final concentration of 
12.5ng/uL. A total of 2uL of cDNA, 25ng/well, was pipetted into the respective well following 
biological treatment group. 8uL of a SYBR Green master mix was then pipetted into respective 
target wells, according to the target gene of interest. SYBR Green master mix comprised of 5uL 
PerfeCTa® SYBR® GreenFastMix® (QuantaBio, 84069), 1uL target primer (Table 3.2), and 2uL 
DEPC H2O per reaction well. All qPCR experiments used 36B4 (RPLP0) as reference gene and 
were plated on a 384 well qPCR plate (Bio-Rad, HSP3805) in technical duplicates. When all 
wells were loaded the plate was centrifuged and placed in CFX384™ Real-Time System C1000 
Table 3.2: Primer List. Target genes of interest used for all cell culture experiments.  
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Touch™ ThemalCycler (Bio-Rad, 1855484) for qPCR analysis. SYBR Green qPCR analysis 
protocol, labeled SYBER BioRad (activation: 2min/95oC, 40 cycles: 5sec/95oC, 30sec/60oC, plate 
read; 31sec/65oC, 5sec/65oC) was performed for all experiments.  
qPCR data was analyzed using Bio-Rad CFX Maestro for Mac 1.0 (Bio-Rad, Version 
4.0.2325.0418). Wells were excluded if their melt curves show a primer dimer formation 
observed as a double peak within the melt curve, or if Cq value was not available due to faulty 
loading. Wells were grouped by biological treatments and target gene, with expression change 
normalized to the reference gene and relative to control, ΔΔCq and 36B4 respectively. Statistical 
significance of expression for biological group vs multiple groups analysis was done by a one-
way ANOVA with Tukey corrections for multiple comparisons. Raw Cq values were extracted 
from CFX Maestro software and analyzed in GraphPad Prism 8.  
3.3 Results 
   3.3.1 atRA response in SNB19 & 
SHSY5Y cells 
 Preliminary experiments with both cell 
lines investigated expression of genes 
associated with atRA metabolism 
(CYP26A1/B1, CRABP2, RAR⍺,β,𝛾), and the 
effect of atRA treatments with comparisons of 
atRA/RAMBA (DX308) co-treatments. These 
experiments had the intended purpose of 
observing an atRA response previously 
mentioned in section 3.1 across both cell lines 
with a comparable increased response upon 
DX308 co-treatment.  
The first experiment revealed that all 
genes of interest were expressed in SNB19 
cells. An atRA response was observed as 
significant increase in CYP26A1 expression. 
Our results show a dose dependent increase in 
atRA response as seen by the significantly 
Figure 3.2: JML_101-SNB19 atRA Treatment. Gene expression of CYP26A1/B1 
and RARs in presence of 1uM atRA, and 1nM atRA. 0.1% DMSO used as control. 
A/B) CYP26A1/B1 gene expression. C/D/E) Target RARs gene expression alone for 
scale. Cell culture treatments run in biological triplicates, qPCR carried out in technical 
duplicates. Significance determined through ΔΔCq one-way ANOVA with Tukey 
corrections for multiple comparisons. (* vs Control, # vs 1nM atRA) (***p<0.001.)  
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increased expression between 1nM and 1uM atRA. All retinoic acid receptors do not show a 
significant increase in expression relative to control under 1nM or 1uM atRA treatment. The 
standard error of mean was relatively large across all target groups due to varied double peaks in 
melt curves. The initial pipetting technique was faulty for <4% of the wells during qPCR plating 
(Figure 3.2). 
In the follow up SNB19 experiment we can see transcription of CYP26A1 again have 
significant increase in expression when compared to lower doses and the control (10nM: 1uM). 
There was also significant increase in atRA signaling when lower doses of atRA were combined 
with low doses of DX308 CYP26A1/B1 inhibitor. We can see this by comparing 10nM 
atRA/100nM DX308 co-treatment with 1uM atRA solo treatment. The increased expression of 
CYP26A1 and CYP26B1 as a factor of atRA response is similar between these combined and 
solo treatments. Because there is a significant difference between the solo atRA and co-DX308 
treatments DX308 exhibits the necessary response for a viable RAMBA. Taken together this 
Figure 3.3: JML_111-SNB19-atRA/DX308. Repeated SNB19 atRA response treatments with added DX308 solo and co-atRA treatments. A) CYP26A1 gene expression. 
B) CYP26B1 gene expression. Cell culture treatments run in biological triplicates; qPCR carried out in technical duplicates. Significance determined through ΔΔCq one-




supports inhibition of atRA metabolism via DX308’s action on CYP26A1/B1 enzyme, observed 
as an increased atRA response under lower atRA concentrations. Additionally we observed 
direct expression of RAR⍺,β,𝛾 in the SNB19 cells; while not significant this does allow for atRA 
directed transcription of RARE (Figure 3.3). 
In the initial experiment with the SHSY5Y cell 
line all genes of interest were expressed in  the 
neuroblastoma immature undifferentiated state. 
Additionally, we observed a dose dependent atRA 
response with 100nM and 10nM atRA treatment. 
Combined treatments of respective atRA 
concentrations with 1uM DX308 do not have 
significant expression of CYP26A1 relative to the solo 
atRA treatment. This indicates that DX308 is not 
potentiating the atRA response. Data also supports 
previous investigations by Armstrong et al. 2007 
where atRA treatments produce an increased atRA 
response relative to control. Importantly SHSY5Y 
cells express CYP26A1, and the respective gene can 
act as atRA response marker in this cell line. In 
addition to atRA response, RARβ is also expressed 
within the cell line. This is important as future 
investigations will target genes associated with Parkinson’s and RARβ promotor sights 
(Niewiadomska-Cimicka et al., 2017). DRD2 and CRABP2 is expressed at low levels for all 
treatment groups (Supplemental Data). It is hypothesized that differentiated SHSY5Y cells will 
have significant increase in DRD expression relative to immature “control” SHSY5Y cells. Note 
that column 2 control wells in RT-qPCR are excluded due to Cq values >2 cycles off biological 
group. This was caused by problems with low cDNA concentration prior to pipetting in the 384 
well plate, the corresponding cDNA tube was incorrectly loaded for reverse transcription 
(jFigure 3.4).  
 
 
Figure 3.4: JML_127-SHSY5Y-atRA/DX308. Initial SHSY5Y cell culture 
investigation for atRA response. CYP26A1 gene expression. Cell culture 
treatments run in biological triplicates; qPCR carried out in technical 
duplicates. Significance determined through ΔΔCq one-way ANOVA with 
Tukey corrections for multiple comparisons.) (* vs control, # vs 1uM DX308, 
@ vs 10nM atRA) (**p<0.01, ***p<0.001.) 
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3.3.2 atRA/TPA Differentiation of SHSY5Y Cells Effect on Dopamine Receptor 
 The specific purpose of the dopaminergic differentiated SHSY5Y experiments was: first, 
to observe SHSY5Y cells increase expression of DRD receptors relative to immature (control) 
SHSY5Y cells, and second; that we can use the differentiated SHSY5Y cells as a dopaminergic 
neuronal model for future DX308 treatments (Figure 3.1).  
 In the first experiment we observe a significant 
increase in CYP26A1 transcription in the atRA/TPA 
treatment group. This suggests that atRA could still be in 
the system at time of harvest, or we are observing 
prolonged 72hr atRA signaling from the initial 10uM 
atRA treatment (Day 0-3). The follow up experiment, 
jml_141, reveals a possible TPA induced CYP26A1 
transcription. While DRD2 receptor does not have 
significant increase in transcription under atRA/TPA 
treatment we do observe a slight increase in expression. 
This is also observed in RARβ expression and allows the 
possibility for atRA targeted transcription of RARE 
described above. Overall, we see atRA signaling on day 7 
of atRA/TPA differentiated SHSY5Y cells; however, the 
means of induction cannot be precisely attributed to the 
presence of atRA. Additionally, the atRA/TPA 
treatment group expressed DRD receptors slightly 
higher than control suggesting that some differentiation 
was taking place. It should be noted that all column 2 control wells were excluded due to 
problems in the culture well where over confluency lead to apoptosis of the entire well 
population and resulted in faulty mRNA at time of harvest. The second study avoided this over 
confluency issue by seeding the plates at 20,000 cells/well instead of 100,000 cells/well. At the 
time of harvest the wells were 70-80% confluent in jml_141.  
 The second experiment with SHSY5YDiff cells supported jml_135, where we again see 
an increase in CYP26A1 expression. Interestingly, DRD1 expression is significantly increased 
while the DRD2 expression is significantly decreased within the atRA/TPA treatment group. 
Figure 3.5: JML_135-SHSY5Y/SHSY5YDiff-atRA/TPA Regiment. 
Secondary SHSY5Y cell culture experiment with interest on atRA/TPA 
induced dopaminergic differentiation. A) CYP26A1 gene expression. B) 
RARb gene expression. C) DRD2 gene expression. Cell culture treatments 
run in biological triplicates, qPCR carried out in technical duplicates. 
Significance determined through ΔΔCq one-way ANOVA with Tukey 
corrections for multiple comparisons.) (* vs control) (***p<0.001) 
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This expression profile is lost within the additional 24hr DX308 treatment group (Figure 3.6). 
This indicates there is possible differentiation in 
treatment group 2 under terminal TPA stimulation, 
but seems to be lost with DX308 24hr treatment. A 
possible explanation for this is TPA induction of DRD 
receptor expression in addition to CYP26A1/B1. This 
is inferred due to the lack of TPA in the 
SHSY5YDiff_DX308 treatment group 24hrs prior to 
harvest. Future experiments will have a TPA only 
treatment group to compare to current atRA/TPA 
differentiation model.  
 This data supports the previous experiment by 
having an atRA response in differentiated SHSY5Y 
cells; while being unable to shed light on the 
additional DX308 treatment within the context of an 
observable atRA response and DRD expression. DRD 
expression profile in atRA/TPA treatment group calls 
for further investigations on TPA directed 
differentiation. Future studies are needed to repeat this 
experiment. Taking special consideration for TPA 




 The overarching goal of these experiments centered around preliminary in vitro modeling 
of gliosis after TBI and the death of dopaminergic neurons found in PD patients with the explicit 
purpose of guided atRA signaling as a mediator of pathogenesis. Importantly we used cost 
effective cell lines; either previously used in the Diaz lab, SHSY5Y, or donated by the Bridges 
lab, SNB19.  SNB19 cells were selected with the intention of modeling a brain injury in a dish 
due to their ability to express GFAP as a marker of reactive gliosis (McMillian et al., 1994). 
SHSY5Y cells were selected due to their diverse ability of differentiation and substantial history 
as a model for PD (Xicoy et al., 2017).  
Figure 3.6: JML_141-SHSY5Y/SHSY5YDiff/SHSY5YDiffDX308. 
Repeated atRA/TPA SHSY5Y cell culture experiment with additional 
24hr DX308 biological treatment group(red star). A) CYP26A1 gene 
expression. B, C) Dopamine receptors gene expression. Cell culture 
treatments run in biological triplicates; qPCR carried out in technical 
duplicates. Significance determined through ΔΔCq one-way ANOVA 
with Tukey corrections for multiple comparisons)  (* vs control, # vs 
1uM DX308) (***p<0.001) 
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 The initial purpose of the experiments needed to prove that both cell lines expressed the 
primary target of novel RAMBA DX308, CYP26A1/B1. Additionally, for the rough models to 
be viable the cell lines also needed to express transport machinery, CRABP2, and atRA directed 
nuclear receptors, RAR⍺,β,𝛾. Observations of these genes expressed in the cell line would 
therefore allow for theoretical atRA guided transcription and subsequent metabolism for 
homeostatic signaling. We intended to induce targeted inhibition of CYP26A1/B1 in order to 
increase the endogenous levels of atRA and subsequent signaling.  Overall our experiments were 
a success in this context. SNB19, SHSY5Y, and SHSY5YDiff all expressed the genes of interest 
pertaining to atRA metabolism and guided transcription. Unfortunately, SNB19 experiments did 
not successfully investigate CRABP2 expression; however, due to the presence of RARs atRA 
directed signaling is still supported in the cell line (Table 3.1, Figure 3.2, 3.3). The secondary 
purpose for all experiments needed to show an atRA response under atRA treatment and DX308 
co-treatment. Successful inhibition of atRA clearance via DX308 would potentiate the atRA 
response under low doses of atRA co-treatment compared to same dose atRA solo treatment. 
With the acceptation of SHSY5YDiff_DX308 treatment group (Figure 3.6, Group 3-red star) we 
observed a dose dependent atRA response across SNB19, SHSY5Y cell lines; and an atRA 
response within the SHSY5YDiff cell line. It should be noted that SHSY5YDiff cell line could 
have CYP26A1 expression mediated by terminal TPA treatment, and future experiments will 
investigate this possibility (Figure 3.5, Group 2). We suspect this due to the observed atRA 
response in jml_135 in SHSY5YDiff, but the loss of this expression profile once DX308 is 
administered post differentiation regiment for 24hrs before harvest (Table 3.1, Figure 3.1-Exp.2). 
Importantly we observed a DX308 potentiated atRA response in the SNB19 cell lines with 
respect to solo atRA treatments (Figure 3.2, 3.3). This is important indicator for future studies 
surrounding gliosis and PD induced stress models as atRA could reduce the pathogenesis of both 
diseases.  
 Finally, this research attempted to differentiate SHSY5Y cell line into a dopaminergic 
neuronal culture following Presgraves et al., 2004 protocol. With respects to DRD expression, 
the atRA/TPA differentiation regiment exhibited an interesting expression profile that was not 
consistent across experiments. DRD1 had significant increase in expression only in one 
experiment while DRD2 had significant decrease in expression in only one experiment. Under an 
atRA/TPA regiment CYP26A1 expression seems to be increased, this effect is lost when the 
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final 24hr treatment is replaced with DX308 alone. Follow up experiments report an altered 
DRD expression between DRD1 and DRD2 when compared to the first experiment. Although 
these expression profiles suggest the possibility for differentiation under atRA/TPA regiment 
repeated SHSY5Y differentiation experiments must be preformed in order to draw more valid 
conclusions. (Figure 3.1, 3.4, 3.5). In vitro dopaminergic neurons are a closer model to PD and 
future studies will utilize the differentiation protocol in coordination with MPTP/MPP+ 
cytotoxicity experiments to assess the viability of atRA mediated cell survival. These 
experiments are only preliminary investigations surrounding DX308’s ability to inhibit atRA 
clearance for neuronal cell lines. Taken together this research has shown a rough model of glial, 
neuronal, and dopaminergic cell lines that can utilize atRA as a homeostatic signaling factor. At 
its basic level we can use this knowledge to investigate DX308 as a therapeutic drug in the CNS 
with the intention of increasing endogenous atRA following TBI or PD diagnosis.    
4. Conclusion & Future Directions 
  4.1 Conclusion 
 These experiments establish a rough in vitro model for investigations surrounding atRA 
signaling and the pharmacological applications of RAMBAs. DX308 inhibition of atRA 
metabolism via CYP26A1/B1 unlocks the possibility for therapeutic intervention in TBI and PD. 
The role of RA signaling following CNS injury is emerging as a primary target for mediation of 
important neuronal genes needed to attenuate TBI and PD. Focusing on particular genes of 
interest under RAR guided transcription is a great place to expand in this area. For example: 
FGF9, BCL-x, NF-KB1, and CAMK2⍺ all have RARβ binding sites and are expressed in either 
SNB19 or SHSY5Y cells (Hodges et al., 2006; Niewiadomska-Cimicka et al., 2017; Rouillard et 
al., 2016). This research was limited to specific cell line expression of atRA synthesis and 
transcription machinery in the CNS and provides the possibility for DX308 application as an 
atRA signaling activator. Activation of atRA signaling pathway following TBI is a major 
contributor to this ideology. The cytotoxicity surrounding the Ca2+/Glu cascade may be 
attenuated by non-canonical atRA signaling through dampening of MAPK activation. 
Significantly lowering Ca2+ stress may halt mitochondrial and cell membrane mediated 
destruction, leading to neuronal survival. As we have seen in these experiments and reported in 
previous literature atRA also retains the ability to control differentiation of some neuronal 
populations. Altering active microglia states to favor M2 phagocytotic differentiation may be 
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under the influence of atRA signaling following TBI. Administration of atRA following TBI in 
mice show a neuroprotective effect and reduction in astrogliosis seven days after the injury. RA 
also has pervasive applications in altering PD pathology. Research previously found oral 
administration of RAR agonist prevented dopaminergic cell loss in the substantia nigra 
supporting the role of RA directed neuronal survival (Katsuki et al., 2009). Further evidence 
surrounds the role RA plays in dopaminergic differentiation and mediated expression of 
dopamine receptors. When considering the beneficial effects of atRA signaling in 
neurodegenerative diseases the therapeutic goal would be to endogenously control the 
intracellular concentrations. One way of increasing intracellular RA is to inhibit CYP26A1/B1 
metabolism. Since DX308 is permeable to the BBB this drug could be administered 
intravenously to combat both TBI and PD. In this work we confirm our hypothesis that DX308 is 
a substrate-based CYP26A1 and B1 inhibitor which inhibit the degradation of atRA in CNS cell 
model and that this degradation is modulated by CYP26A1 and B1 which are expressed in these 
cells and have their expression increase after atRA treatment. Additional work is needed to fully 
demonstrate the therapeutic utility of DX308 on the treatment of neurodegenerative diseases but 
based on our preliminary experiments it represents a promising candidate for further in vitro and 
in vivo studies. 
 4.2 Future Directions 
 In the immediate realm of this research repeated RT-qPCR should be performed for all 
experiments in order to support these preliminary findings. Additionally, the intracellular carrier 
protein for retinoic acid directed transcription, CRABP2, should be added to the gene target list 
for the repeated experiments. Other target genes for SNB19 include: GFAP, FGF9, BCL-X, and 
EAAT1 (SLC1A3). These genes have either been found to be expressed in the specific cell line 
or have RARβ binding sites for RA guided transcription (Rouillard et al., 2016; Niewiadomaska-
Cimicka, 2017). GFAP is an important gene target as it can be considered a marker for gliosis in 
most astroglia cell lines (Verkhratsky et al., 2014). Another gene of interest for the SHSY5Y cell 
line is CAMK2⍺ which is expressed in the cell line and has RARβ binding sites. NfKB1 also has 
RARβ binding sites and should be added to the list of target genes for future investigations. 
These genes are useful as canonical and non-canonical signaling may lend supporting evidence 
for RA mediation of inflammation and excitotoxicity in TBI and PD pathology. Cell cultures 
would undergo similar protocols for RAMBA co-treatments with special interest on the 
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expression relationship relative to an observed atRA response. Other cell culture experiments 
that can end in RT-qPCR would revolve around cytotoxicity models and how they affect target 
gene transcription relative to atRA and DX308 co-treatments. SNB19 can be treated with LPS, 
ROS, and TNF⍺ in tandem with atRA or DX308 co-treatments to model TBIs and therapeutic 
intervention with respect to the effects of atRA directed signaling. Special interest would 
consider the relationship between activated gliosis and atRA response by monitoring the 
expression of GFAP and CYP26A1/B1 respectively. SHSY5Y cells can undergo MPTP/MPP+ 
treatments to model neurodegeneration similar to PD. The goal would be to observe how 
modeling PD in vitro with SHSY5YDiff would affect the atRA response and target genes 
associated with neuroinflammation and protection. In coordination with these RT-qPCR 
experiments ELISA assays would need to be performed in tandem with cell culture constraints. 
Under the same cytotoxicity/PD model and atRA/DX308 co-treatments ELISA antibodies would 
look for TNF⍺, IL-1β, and IL-6 as indicators of inflammation following cell culture treatments. 
Anti-inflammatory cytokines under investigation would include: IL-4, IL-10, BDNF⍺, and TGF-
β. Understanding the inflammatory signaling after modeling the neurovegetative disease in 
coordination with atRA/DX308 treatments would give tremendous insight on the possible 
neuroprotective effects of both atRA and the novel RAMBA, DX308. Together this research 
could be published as the discovery of a new RAMBA that can be used to diminish the 2o insult 
of TBIs or combat the pathogenesis of PD by alleviating the death of dopaminergic neurons. 
atRA has an important regulatory role in the central nervous system, unlocking the signaling 
effects of increased endogenous atRA as it pertains to TBI and PD could be the fundamental step 
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